Literature DB >> 11043807

Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis.

S Hosoda1, H Takimura, M Shibayama, H Kanamura, K Ikeda, H Kumada.   

Abstract

Psychiatric symptoms during interferon (IFN) therapy for viral hepatitis have been a crucial problem in consultation-liaison psychiatry. However, there have been few studies on psychiatric management for these symptoms and their prognosis. Among 943 patients who were treated with IFN for chronic hepatitis C between 1991 and 1995, 43 patients (4.6%) developed psychiatric symptoms during IFN treatment. Three patients (0.3%), with pre-existing psychiatric disorders showed aggravated symptoms and were excluded from the study. All three patients were able to finish the IFN therapy with psychiatric management. Forty patients (4.2%) manifested psychiatric symptoms induced by IFN. Thirteen patients (1.4%) were diagnosed as anxiety disorder and 21 patients (2.2%) revealed mood disorder with depressive features. There were other psychiatric disorders in six patients (0.6%), including psychotic disorder with delusions/hallucinations in four patients (0.4%), mood disorder with manic features in one patient (0.1%) and delirium in one patient (0.1%). Women developed psychiatric symptoms significantly more than men. Ten of 40 patients (25%) stopped IFN treatment because of manifesting psychiatric symptoms induced by IFN. Twelve patients (30%) required psychiatric treatment for more than 24weeks after ceasing IFN, and seven patients still had anxiety, insomnia and mild hypothymia at the end of the present study. Statistical analysis revealed that IFN-beta therapy and psychiatric manifestations including psychotic symptoms, delirium and manic symptoms were significantly related to long-term psychiatric problems. There are considerable numbers of patients who have required long-term psychiatric management even after cessation of IFN treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11043807     DOI: 10.1046/j.1440-1819.2000.00754.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  15 in total

1.  Management of Psychiatric Disease in Hepatitis C Treatment Candidates.

Authors:  Francis Lotrich
Journal:  Curr Hepat Rep       Date:  2010-04-06

2.  Psychosis as an adverse effect of monoclonal antibody immunotherapy.

Authors:  Norah Essali; David R Goldsmith; Laura Carbone; Brian J Miller
Journal:  Brain Behav Immun       Date:  2019-06-03       Impact factor: 7.217

3.  Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients.

Authors:  Ghanshyam N Pandey; Xinguo Ren; Hooriyah S Rizavi; Hui Zhang
Journal:  Schizophr Res       Date:  2015-03-04       Impact factor: 4.939

Review 4.  The role of the kynurenine metabolism in major depression.

Authors:  Aye-Mu Myint; Markus J Schwarz; Norbert Müller
Journal:  J Neural Transm (Vienna)       Date:  2011-12-03       Impact factor: 3.575

Review 5.  Neuropsychiatric side effects of interferon-alfa therapy.

Authors:  Arthur R Van Gool; Wim H J Kruit; Frederike K Engels; Gerrit Stoter; Marjolein Bannink; Alexander M M Eggermont
Journal:  Pharm World Sci       Date:  2003-02

6.  Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.

Authors:  Marcia D McNutt; Shuling Liu; Amita Manatunga; Erica B Royster; Charles L Raison; Bobbi J Woolwine; Marina F Demetrashvili; Andrew H Miller; Dominique L Musselman
Journal:  Neuropsychopharmacology       Date:  2012-02-22       Impact factor: 7.853

7.  Psychiatric clearance for patients started on interferon-alpha-based therapies.

Authors:  Francis E Lotrich
Journal:  Am J Psychiatry       Date:  2013-06       Impact factor: 18.112

8.  Hepatitis B and C among veterans on a psychiatric ward.

Authors:  James H Tabibian; Donna A Wirshing; Joseph M Pierre; Lisa H Guzik; Michael D Kisicki; Itai Danovitch; Shirley J Mena; William C Wirshing
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

9.  General medical with depression drugs associated.

Authors:  Donald Rogers; Ronald Pies
Journal:  Psychiatry (Edgmont)       Date:  2008-12

Review 10.  Psychiatric treatment considerations with direct acting antivirals in hepatitis C.

Authors:  Sanjeev Sockalingam; Alice Tseng; Pierre Giguere; David Wong
Journal:  BMC Gastroenterol       Date:  2013-05-14       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.